The critical number of genes which can predict a particular genotype is a matter of discussion. Downing pointed out that as few as 20 genes may be necessary for an accurate prediction of subsets and prognosis; these genes should be specifically studied, perhaps by methods like reverse transcription polymerase chain reaction (RT-PCR) or flow cytometry (FC) (Downing in Carroll et al 5 ). FC, which shows the expression of molecules in mutual context on individual cells, appears optimal for such analysis.
The present study (Microarray-guided FC) is designed to systematically screen for genes within the existing expression profiling studies on childhood acute lymphoblastic leukemia (ALL). 1, 3 The genes, which are identified as best correlating with the pediatric ALL subgroups (E2A/PBX1, MLL, TEL/AML1, BCR/ ABL, 'novel' and hyperdiploid genotypes; patients who later relapsed and those who developed therapy-induced acute myeloblastic leukemia), are selected. After recalculation just for the B precursor ALL cases, we select the genes in which the difference in expression is likely to be observed at the protein level. Next, we select molecules with suitable cellular localization (nonsecreted proteins) and with an available mAb. Reactivity and specificity of mAbs are tested in healthy peripheral blood cells and/or in cell lines. The respective molecules are investigated by four-color FC in diagnostic bone marrow (BM) samples. Five molecules have proceeded into this step (CD44, CD27, CD49f, CD247 and CD103). We present here the results of CD44 and CD27 expression, which are investigated in the largest cohort.
A total of 66 patients with B-cell precursor ALL and 14 patients with T lineage ALL were considered to enter CD44 and CD27 investigation. Expression profiling found the gene for CD44 (Hermes, Pgp-1) to be one of the best correlating with the MLL genotype and with the subgroup of T-ALL patients who later developed hematological relapse. 1, 3 Although MLLR pos blasts in our cohort did show CD44 positivity, so far we have not observed a higher CD44 expression compared to other CD44 pos B-cell precursor ALL cases (Figures 1a, 2a ). In addition, CD44 expression significantly correlated with higher risk T-ALL (P ¼ 0.032) (Figure 2b ). This also indicates that the current risk stratification of the T-ALL patients within the ALL-IC BFM2002 protocol (based on age, leukocyte count at presentation, early treatment response and unfavorable molecular genetics, as in other major frontline therapy protocols) corresponds to the true biological risk. Furthermore, CD44 expression was significantly lower in TEL/ AML1 pos ALL (Po0.0001), which is in line with the observation of one of the two expression profiling studies. 3 The association with TEL/AML1 genotype was also found in CD27 (TNFRSF7) gene expression, 1 but another expression profiling study 3 showed only a correlation with BCR/ABL genotype. We found a strong correlation of CD27 with TEL/ AML1 positivity. CD27 pos blasts above 30% were detected in 20/21 and 2/35 patients with TEL/AML1 pos and TEL/AML1 neg ALL, respectively (Po0.0001) (Figure 1a ). Since the opposite correlations with TEL/AML1 were observed for CD27 and CD44, we analyzed the composite picture of the expression of these two molecules simultaneously (Figure 1a, b To compare the value of CD44 and CD27 with the other expression profiling data for the prediction of TEL/AML1 status, we used the same plot as described previously in the FC metaanalyses 6 ( Figure 1c ). This format depicts graphically the predictive value of each probe set or molecule for the TEL/AML1 status. Each probe set or molecule is separately compared to its optimal cutoff value in all BCP ALL patients of the respective cohort. The probe-set-specific optimal cutoff value was determined using a statistical software R (http://www.r-project.org). The optimal cutoff value is the one that leads to the best resolution between TEL/AML1 pos and TEL/AML1 neg subsets, judging by the distance from a noncorrelating diagonal. The percentage of TEL/AML1 neg patients above the cutoff value is compared to the respective value in TEL/AML1 pos patients. The overall predictive values for CD44 and CD27 are 93 and 95% in FC, 82 and 91% in Yeoh, 1 and 90 and 90% in Ross, 3 respectively. The difference in predictive values is in compliance with the fact that FC can investigate the expression of tested molecules on pure ALL cells. We studied the other molecules (CD49f, CD247 and CD103) in specimens of fewer patients and thus it would be too early to establish their predictive values. 1 Probe set numbers 40493_at (CD44) and 38578_at (CD27). (c) The TEL/AML1 predictive value of CD44 and CD27, detected by FC or in two expression profiling studies. Comparison to the other 12 623 probe sets analyzed in Yeoh et al. 1 Noncorrelating genes are near the hatched diagonal. An optimal cutoff value was found for each probe set based on the best discrimination of TEL/AML1
pos from other B-precursor ALL cases (largest distance from the noncorrelating diagonal). Circles represent individual probe sets (values corresponding to the best CD44 and CD27 probe sets are enlarged). Squares represent CD44 and CD27 from Ross et al 3 (probe set numbers 212063_at for CD44 and 206150_at for CD27), triangles show CD44 and CD27 by FC, this cohort. In expression profiling studies, the best correlating probe sets were used in both instances.
Correspondence
The principle that class-defining genes may be selected within microarray data has been suggested previously (Downing in Carroll et al 5 ). The results of the presented screening strategy prove this principle. Lack of information on protein expression appeared to be the most limiting factor reducing the number of candidate genes in the final FC testing. Improbability of the cell-bound form also excluded molecules during the screening for FC -these secreted molecules may be studied by protein biochemistry. Although cytometric studies on molecules that came from a systematic screening strategy in microarrays have not been presented yet, one new molecule (CD58) has been introduced into FC testing based on expression profiling. 7 The presented data not only show that information from microarrays can be transferred to cell-based investigation by FC, but also that the composite microarray information can be successfully replaced by strong predictors like CD44 and CD27. The ongoing project Microarray-guided FC tests whether other molecules can be found with comparable or better predictive values for ALL genotype and prognosis. 
